全球莱姆病诊断市场 - 2022-2029

市场动态

由于莱姆病患病率的上升和诊断技术的进步，对莱姆病诊断的需求增加，推动了市场增长。

技术进步和不断增加的新产品推出预计将推动市场增长。

全球莱姆病诊断市场的增长受到多种因素的推动，包括各种新的创新和产品发布，以及莱姆病患病率的上升。据莱姆病协会称，莱姆病是世界上最常见的蜱传细菌性疾病。

市场正在见证新的经过验证的诊断测试的推出和批准，以准确诊断莱姆病。例如，2019 年 7 月，Zeus Scientific 宣布 Zeus ELISA Borrelia VlsE1/pepC10 IgG/IgM、Borrelia burgdorferi IgG/IgM、Borrelia burgdorferi IgM 和 Borrelia burgdorferi IgG Test Systems 等莱姆病诊断测试获得食品药品监督管理局的批准。管理局（美国食品和药物管理局）。）有一个扩展的市场许可。这些诊断测试同时使用两种□联免疫吸附测定 (EIA)，而不是传统的 EIA 和蛋白质印迹测试的两步过程。

2020 年 2 月，DiaSorin 获得了美国 FDA 的 Liaison LimeTotal Antibody Plus Assay 和 Liaison LimeTotal Antibody Plus Control Set 许可。该测定利用化学发光来检测人血清和血浆样品中针对伯氏疏螺旋体的 IgG 和 IgM 抗体。

此外，每个机构都为莱姆病诊断测试的开发提供资助。例如，2019 年 7 月，Enable Biosciences 获得了隶属于美国国立卫生研究院 (NIH) 的美国国家过敏和传染病研究所 (NIAID) 的为期一年的 I 期资助，用于开发改进的莱姆病测试. 它获得了 225,000 美元的小企业创新研究 (SBIR) 资助。

缺乏对莱姆病诊断的认识预计会阻碍市场增长。

预计对莱姆病诊断缺乏认识将阻碍预测期内的市场增长。因为很少有人知道莱姆病及其诊断。在农村地区，缺乏对该疾病及其诊断的知识正在限制市场增长。

行业分析

全球莱姆病诊断市场根据波特五力、监管分析、供应链分析、定价分析、产品创新和未满足的需求等各种行业因素对市场进行了深入分析。 .

全球莱姆病诊断市场报告提供对大约 45 多个市场数据表、40 多个数字和 180 页的访问。

内容

第一章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

• 市场影响因素
  • 驱动程序
    • 莱姆病患病率上升
    • 不断发展的技术进步
  • 限制因素
    • 对莱姆病的认识不足
  • 商机
  • 影响分析

第五章行业分析

• 波特五力分析
• 监管分析
• 供应链分析
• 定价分析
• 产品创新
• 未满足的需求

第 6 章通过诊断技术

• 血清学检测
• 尿抗原检测
• 淋巴细胞转化试验
• 免疫荧光染色
• 核酸检测
• 其他

第 7 章按应用程序

• 医院
• 公共/私人检验机构
• 医务室

第 8 章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第 9 章竞争格局

• 主要发展和战略
• 公司份额分析
• 按产品类型进行基准测试
• 值得关注的重点公司列表

第 10 章公司简介

• 雅培实验室
  • 公司概况
  • 按产品类型划分的产品组合和内容
  • 主要亮点
  • 财务摘要
• T2 Biosystems, Inc.
• Bio-Rad Laboratories, Inc.
• Alere Inc.
• Roche Diagnostics International Ltd.
• Graphene Frontiers, LLC
• Covance Inc.
• Immunetics Inc.
• GlaxoSmithKline Pharmaceuticals Ltd.
• Boulder Diagnostics Inc.

第11章 全球莱姆病诊断市场-DataM

Market Overview

Lyme Disease Diagnostics Market size was valued US$ 2.53 billion in 2021 and is estimated to reach US$ 4.27 billion by 2029, growing at a CAGR of 8.9% during the forecast period (2022-2029).

Lyme disease diagnostics are the diagnostic tests used for diagnosing the signs & symptoms, and other diseases such as neurologic, cardiac symptoms associated with Lyme disease. These diagnostic tests identify the antibodies produced by the immune system in response to the infection. Lyme disease diagnostics predicts the likelihood of whether the patient is exposed to infected blacklegged ticks.

Market Dynamics

The market growth is driven by the rising demand for Lyme disease diagnosis due to the rising prevalence of Lyme disease as well as technological advancements in diagnostics.

Increasing advancements in technology and introduction of novel products are expected to drive market growth.

The global Lyme disease diagnostics market growth is driven by several factors, such as various new innovations and products release in market and rising prevalence of Lyme disease. According to the Lyme Disease Association, Lyme Disease is the most common tick-borne bacterial infection in the world.

The market is witnessing the launch and clearance of new validated diagnostic tests for accurate diagnosis of Lyme Disease. For instance, in July 2019, Zeus Scientific had received the expanded market clearance from Food and Drug Administration (US FDA) for its diagnostic tests such as Zeus ELISA Borrelia VlsE1/pepC10 IgG/IgM, Borrelia burgdorferi IgG/IgM, Borrelia burgdorferi IgM and Borrelia burgdorferi IgG Test Systems for Lyme disease. These diagnostic tests include the concurrent use of two enzyme immunoassays (EIA), instead of the existing two-step process requiring an initial EIA test followed by a Western Blot protein test.

In February 2020, DiaSorin had received clearance from the Food and Drug Administration (US FDA) for Liaison Lyme Total Antibody Plus assay and Liaison Lyme Total Antibody Plus Control Set. This assay uses chemiluminescence to detect lgG and IgM antibodies to Borrelia burgdorferi in human serum and plasma samples.

Moreover, the organizations are providing grants for the development of Lyme disease diagnostic tests. For instance, in July 2019, Enable Biosciences had received the award of one-year Phase I Small Business Innovative Research (SBIR) grant for USD 225,000 from the National Institute of Allergy & Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) for the development of an improved Lyme disease test.

Scarcity of awareness associated with Lyme disease diagnostics is expected to hamper the market growth.

Unawareness about the Lyme disease diagnostic is expected to hinder the market's growth over the forecast period. As few people know about the disease and its diagnosis. In rural areas people lack knowledge related to disease and its diagnosis hence restrains the growth of market.

Industry Analysis

The global Lyme disease diagnostics market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Product Innovation, Unmet Needs.

Segment Analysis

Diagnostic technology segment is expected to hold the largest market share in global lyme disease diagnostics market

The global Lyme disease diagnostics market is segmented based on diagnostic technology as a serological test, urine antigen tests, lymphocytic transformation test, immunofluorescent staining, nucleic acid test, and others. The serological test segment accounts for the highest market share due to the high usage of Serological tests for diagnosing Lyme disease. This test involves the initial screening assay for the detection of antibodies leading to the development of Lyme Disease. Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot are the commonly used serological tests for Lyme Disease diagnosis.

The urine antigen tests segment is expected to have positive market growth due to growing research and development activities for urine antigen tests for the diagnosis of Lyme Disease. Ceres Nanosciences had developed the urine-based Nanotrap Lyme Antigen test for detecting Lyme disease. The urine antigen tests segment is dominated by the presence of the development of urine antigen tests products that have received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). For instance, In Jun 2022, Adaptive Biotechnologies decided to interpret adaptive immune structure genetics to clinical device for the diagnosis of disease using T-Detect Lyme.

Further, the market is also classified based on application into hospitals, public/private laboratories, and physician's offices. The hospital segment is expected to witness the highest market growth due to Lyme Disease diagnostic tests' high usages with the rising hospitalization cases.

The public/private laboratories segment is expected to have positive market growth due to the increase in the number of public/private laboratories for diagnosing Lyme Disease. The majority of the public/private laboratories are providing Lyme disease testing using urine or other body fluids and serological tests.

Geographical Analysis

North America region holds the largest market share in the global Lyme disease diagnostics market

By region, the global Lyme disease diagnostics market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, the North American region dominated the global Lyme disease diagnostics market due to the high prevalence of Lyme Disease. According to the Centres for Disease Control and Prevention (CDC), approximately 300,000 people are suffering from Lyme Disease in the United States every year. There are rising government and private institutes initiatives to treat and diagnose Lyme Diseases in countries in the region. There are a majority of the companies developing Lyme Diseases diagnostics. Several institutes have increased their focus on developing novel diagnostic tests. For instance, in November 2019, the National Institutes of Health (NIH) had planned a five-year strategic plan to accelerate research initiatives leading to better prevention, diagnosis, and treatment of tick-borne diseases. In March 2020, a leading sponsor of Lyme disease research in the United States, Bay Area Lyme Foundation had opened the San Diego collection site of the Bay Area Lyme Foundation's Lyme Disease Biobank to provide researchers with blood and urine samples from people with early Lyme Disease from multiple endemic regions across the country.

Europe is expected to witness positive market growth due to the drastic increase in Lyme Disease cases. Over the last decade, the incidence of cases of Lyme Disease has increased by three times in Europe. The market is witnessing the development of novel diagnostic tests with technological advancement. These emerging diagnostic tests would help in the accurate diagnosis of Lyme Disease.

Competitive Landscape

The global Lyme disease diagnostics market is fragmented with the presence of many local and international players. Abbott Laboratories, Bio-Rad Laboratories, Affymetrix, Inc., Roche Diagnostics, T2 Biosystems, and GlaxoSmithKline Pharmaceuticals are the leading companies with a significant market share.

Technology advancement, product diversification, market expansion, and new product launches intensify the market competition. For instance, T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease.

Ceres Nanosciences had developed the urine-based Nanotrap Lyme Antigen test for detecting Lyme disease. This Nanotrap enrichment technology would detect Lyme antigens in patient urine at the early stages of the disease. This technology would use Nanotrapto uses hydrogel particles to capture, preserve, and enrich target analytes and allow the more sensitive detection of low abundance molecules.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to increase the demand for Lyme Disease Diagnostics and their expansion across the globe. For instance, in June 2019, Qiagen and DiaSorin entered into the collaboration to develop an ultra-sensitive QuantiFERON-based diagnostic test to detect Lyme disease early. QuantiFERON technology comprises a sample collection component with its assay stimulus/initiation and a read-out component to measure the stimulus's signals. This component would be run on DiaSorin's LIAISON family of fully-automated analyzers.

In July 2019, PerkinElmer had entered into the collaboration with and EverlyWell for accelerating the innovation in and accessibility of consumer-initiated health testing, by adding PerkinElmer's CLIA-certified and CAP-accredited lab facilities to EverlyWell's network of laboratory providers. The first offerings resulting from this collaboration include the Lyme disease and food sensitivity tests for which PerkinElmer would provide the expertise behind EverlyWell's panels.

Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

PLEX-ID: It is molecular diagnostic technology based which integrates mass spectrometry and PCR technology and identifies and characterises wide range of micro-organisms.

Key Developments: In Oct 2020, Abbott got emergency use authorization for their COVID-19 IgM antibody blood test from the FDA.

The global Lyme disease diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. Rising prevalence concerning Lyme disease
    • 4.1.1.2. Growing Technological Advancement
  • 4.1.2. Restraints:
    • 4.1.2.1. Scarcity of awareness about Lyme disease
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Regulatory Analysis
• 5.3. Supply Chain Analysis
• 5.4. Pricing Analysis
• 5.5. Product Innovations
• 5.6. Unmet Needs

6. By Diagnostic Technology

• 6.1. Introduction
  • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Technology Segment
  • 6.1.2. Market Attractiveness Index, By Diagnostic Technology Segment
• 6.2. Serological Test
  • 6.2.1.1. Introduction
  • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 6.3. Urine Antigen Tests
• 6.4. Lymphocytic Transformation Test
• 6.5. Immunofluorescent Staining
• 6.6. Nucleic Acid Test
• 6.7. Others

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 7.1.2. Market Attractiveness Index, By Application Segment
• 7.2. Hospitals
  • 7.2.1.1. Introduction
  • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Public/Private Laboratories
• 7.4. Physician's Office

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Technology
  • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Technology
  • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Italy
    • 8.3.5.5. Spain
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Technology
  • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Technology
  • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. Australia
    • 8.5.5.5. Rest of Asia Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Technology
  • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape

• 9.1. Key Developments and Strategies
• 9.2. Company Share Analysis
• 9.3. Product Types Benchmarking
• 9.4. List of Key Companies to Watch

10. Company Profiles

• 10.1. Abbott Laboratories
  • 10.1.1. Company Overview
  • 10.1.2. Product Type Portfolio and Description
  • 10.1.3. Key Highlights
  • 10.1.4. Financial Overview
• 10.2. T2 Biosystems, Inc.
• 10.3. Bio-Rad Laboratories, Inc.
• 10.4. Alere Inc.
• 10.5. Roche Diagnostics International Ltd.
• 10.6. Graphene Frontiers, LLC
• 10.7. Covance Inc.
• 10.8. Immunetics Inc.
• 10.9. GlaxoSmithKline Pharmaceuticals Ltd.
• 10.10. Boulder Diagnostics Inc.

LIST NOT EXHAUSTIVE

11. Global Lyme Disease Diagnostics Market - DataM

• 11.1. Appendix
• 11.2. About Us and End User
• 11.3. Contact Us